Dose levels for patients enrolled at MDACC in study INCB18424-251. (A) Initial doses were assigned by the clinical study protocol amendment in operation at the time of enrollment. Seventy-nine of 107 patients began dosing with twice-daily regimens ranging from 10 mg BID to 50 mg BID; the proportion of all patients starting with BID doses at a given dose group is shown. (B) Fifty-eight patients remained on study at the time of data analysis; the proportion of patients receiving the indicated BID doses is shown.